Browsing by Author Christodoulou, C.

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Jump to: Α Β Γ Δ Ε Ζ Η Θ Ι Κ Λ Μ Ν Ξ Ο Π Ρ Σ Τ Υ Φ Χ Ψ Ω
or enter first few letters:  
View Option
Showing results 10 to 25 of 25 < previous 
TitleAuthor(s)Issue date???itemlist.???
Paclitaxel and bevacizumab as first line combined treatment in patients with metastatic breast cancer: the Hellenic Cooperative Oncology Group experience with biological marker evaluationFountzilas, G.; Kourea, H. P.; Bobos, M.; Televantou, D.; Kotoula, V.; Papadimitriou, C.; Papazisis, K. T.; Timotheadou, E.; Efstratiou, I.; Koutras, A.; Pentheroudakis, G.; Christodoulou, C.; Aravantinos, G.; Miliaras, D.; Petraki, K.; Papandreou, C. N.; Papakostas, P.; Bafaloukos, D.; Repana, D.; Razis, E.; Pectasides, D.; Dimopoulos, A. M.24-Nov-2015-
Paclitaxel and epirubicin versus paclitaxel and carboplatin as first-line chemotherapy in patients with advanced breast cancer: a phase III study conducted by the Hellenic Cooperative Oncology GroupFountzilas, G.; Kalofonos, H. P.; Dafni, U.; Papadimitriou, C.; Bafaloukos, D.; Papakostas, P.; Kalogera-Fountzila, A.; Gogas, H.; Aravantinos, G.; Moulopoulos, L. A.; Economopoulos, T.; Pectasides, D.; Maniadakis, N.; Siafaka, V.; Briasoulis, E.; Christodoulou, C.; Tsavdaridis, D.; Makrantonakis, P.; Razis, E.; Kosmidis, P.; Skarlos, D.; Dimopoulos, M. A.24-Nov-2015-
Paclitaxel and gemcitabine vs. paclitaxel and pegylated liposomal doxorubicin in advanced non-nasopharyngeal head and neck cancer. An efficacy and cost analysis randomized study conducted by the Hellenic Cooperative Oncology GroupFountzilas, G.; Papakostas, P.; Dafni, U.; Makatsoris, T.; Karina, M.; Kalogera-Fountzila, A.; Maniadakis, N.; Aravantinos, G.; Syrigos, K.; Bamias, A.; Christodoulou, C.; Economopoulos, T.; Kalofonos, H.; Nikolaou, A.; Angouridakis, N.; Stathopoulos, G.; Bafaloukos, D.; Pavlidis, N.; Daniilidis, J.24-Nov-2015-
Palliative chemotherapy in elderly patients with common metastatic malignancies: A Hellenic Cooperative Oncology Group registry analysis of management, outcome and clinical benefit predictorsPentheroudakis, G.; Fountzilas, G.; Kalofonos, H. P.; Golfinopoulos, V.; Aravantinos, G.; Bafaloukos, D.; Papakostas, P.; Pectasides, D.; Christodoulou, C.; Syrigos, K.; Economopoulos, T.; Pavlidis, N.24-Nov-2015-
Phase I study of etoposide, cisplatin and irinotecan triplet in patients with advanced-stage small-cell lung cancerBriasoulis, E.; Samantas, E.; Kalofonos, H.; Skarlos, D.; Makatsoris, T.; Christodoulou, C.; Fountzilas, G.; Bamias, A.; Dimopoulos, M. A.; Kosmidis, P.; Pavlidis, N.24-Nov-2015-
Phase II study of docetaxel-vinorelbine in platinum-resistant, paclitaxel-pretreated ovarian cancerAravantinos, G.; Bafaloukos, D.; Fountzilas, G.; Christodoulou, C.; Papadimitriou, C.; Pavlidis, N.; Kalofonos, H. P.; Gogas, H.; Kosmidis, P.; Dimopoulos, M. A.24-Nov-2015-
Postoperative dose-dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high-risk operable breast cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology GroupFountzilas, G.; Skarlos, D.; Dafni, U.; Gogas, H.; Briasoulis, E.; Pectasides, D.; Papadimitriou, C.; Markopoulos, C.; Polychronis, A.; Kalofonos, H. P.; Siafaka, V.; Kosmidis, P.; Timotheadou, E.; Tsavdaridis, D.; Bafaloukos, D.; Papakostas, P.; Razis, E.; Makrantonakis, P.; Aravantinos, G.; Christodoulou, C.; Dimopoulos, A. M.24-Nov-2015-
Postoperative dose-dense sequential versus concomitant administration of epirubicin and paclitaxel in patients with node-positive breast cancer: 5-year results of the Hellenic Cooperative Oncology Group HE 10/00 phase III TrialGogas, H.; Dafni, U.; Karina, M.; Papadimitriou, C.; Batistatou, A.; Bobos, M.; Kalofonos, H. P.; Eleftheraki, A. G.; Timotheadou, E.; Bafaloukos, D.; Christodoulou, C.; Markopoulos, C.; Briasoulis, E.; Papakostas, P.; Samantas, E.; Kosmidis, P.; Stathopoulos, G. P.; Karanikiotis, C.; Pectasides, D.; Dimopoulos, M. A.; Fountzilas, G.24-Nov-2015-
Prognostic significance of UBE2C mRNA expression in high-risk early breast cancer. A Hellenic Cooperative Oncology Group (HeCOG) StudyPsyrri, A.; Kalogeras, K. T.; Kronenwett, R.; Wirtz, R. M.; Batistatou, A.; Bournakis, E.; Timotheadou, E.; Gogas, H.; Aravantinos, G.; Christodoulou, C.; Makatsoris, T.; Linardou, H.; Pectasides, D.; Pavlidis, N.; Economopoulos, T.; Fountzilas, G.24-Nov-2015-
A randomized phase II study of carboplatin plus pegylated liposomal doxorubicin versus carboplatin plus paclitaxel in platinum sensitive ovarian cancer patients: a Hellenic Cooperative Oncology Group studyBafaloukos, D.; Linardou, H.; Aravantinos, G.; Papadimitriou, C.; Bamias, A.; Fountzilas, G.; Kalofonos, H. P.; Kosmidis, P.; Timotheadou, E.; Makatsoris, T.; Samantas, E.; Briasoulis, E.; Christodoulou, C.; Papakostas, P.; Pectasides, D.; Dimopoulos, A. M.24-Nov-2015-
A randomized phase III study comparing three anthracycline-free taxane-based regimens, as first line chemotherapy, in metastatic breast cancer: a Hellenic Cooperative Oncology Group studyFountzilas, G.; Dafni, U.; Dimopoulos, M. A.; Koutras, A.; Skarlos, D.; Papakostas, P.; Gogas, H.; Bafaloukos, D.; Kalogera-Fountzila, A.; Samantas, E.; Briasoulis, E.; Pectasides, D.; Maniadakis, N.; Matsiakou, F.; Aravantinos, G.; Papadimitriou, C.; Karina, M.; Christodoulou, C.; Kosmidis, P.; Kalofonos, H. P.24-Nov-2015-
Rituximab in combination with CNOP chemotherapy in patients with previously untreated indolent non-Hodgkin's lymphomaEconomopoulos, T.; Fountzilas, G.; Pavlidis, N.; Kalantzis, D.; Papageorgiou, E.; Christodoulou, C.; Hamilos, G.; Nicolaides, C.; Dimopoulos, M.24-Nov-2015-
Seasonality of violent suicides in the Athens greater areaChristodoulou, C.; Papadopoulos, I. N.; Douzenis, A.; Kanakaris, N.; Leukidis, C.; Gournellis, R.; Vlachos, K.; Papadopoulos, F. C.; Lykouras, L.24-Nov-2015-
Survivin and glycodelin transcriptional activity in node-positive early breast cancer: mRNA expression of two key regulators of cell survivalKostadima, L.; Pentheroudakis, G.; Fountzilas, G.; Dimopoulos, M.; Pectasides, D.; Gogas, H.; Stropp, U.; Christodoulou, C.; Samantas, E.; Wirtz, R.; Hennig, G.; Bafaloukos, D.; Arapantoni, P.; Kalofonos, H.; Papakostas, P.; Economopoulos, T.; Bamias, A.; Pavlidis, N.24-Nov-2015-
Trastuzumab combined with pegylated liposomal doxorubicin in patients with metastatic breast cancer. phase II Study of the Hellenic Cooperative Oncology Group (HeCOG) with biomarker evaluationChristodoulou, C.; Kostopoulos, I.; Kalofonos, H. P.; Lianos, E.; Bobos, M.; Briasoulis, E.; Gogas, H.; Razis, E.; Skarlos, D. V.; Fountzilas, G.24-Nov-2015-
Triple-negative phenotype is of adverse prognostic value in patients treated with dose-dense sequential adjuvant chemotherapy: a translational research analysis in the context of a Hellenic Cooperative Oncology Group (HeCOG) randomized phase III trialSkarlos, P.; Christodoulou, C.; Kalogeras, K. T.; Eleftheraki, A. G.; Bobos, M.; Batistatou, A.; Valavanis, C.; Tzaida, O.; Timotheadou, E.; Kronenwett, R.; Wirtz, R. M.; Kostopoulos, I.; Televantou, D.; Koutselini, E.; Papaspirou, I.; Papadimitriou, C. A.; Pectasides, D.; Gogas, H.; Aravantinos, G.; Pavlidis, N.; Arapantoni, P.; Skarlos, D. V.; Fountzilas, G.24-Nov-2015-